SCHEMBL26244635

SCHEMBL26244635

CCOC(=O)c1cc2cc(C)cc(OC)c2o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
PIM1 P11309 1/20 0.49
LMNA P02545 1/20 0.43
RECQL P46063 1/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B2 P37059 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HTT P42858 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
ALOX5 P09917 1/20 0.40
AKR1B1 P15121 1/20 0.39
GAA P10253 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GPR35 Q9HC97 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7389995 0.86 PIM1 (0.68) MAPTPIM1LMNARECQLKMT2A
Hydrochloric Acid SCHEMBL6986601 0.85 MAPT (0.46) MAPTPIM1LMNARECQLKMT2A
SCHEMBL26244631 0.84 L3MBTL1 (0.48) MAPTLMNARECQLALDH1A1HDAC4
SCHEMBL7390366 0.83 MAPT (0.45) MAPTPIM1LMNARECQLKMT2A
SCHEMBL26244633 0.82 MAOB (0.47) MAPTLMNARECQLKMT2AALDH1A1
SCHEMBL8057737 0.82 PIM1 (0.70) MAPTPIM1LMNARECQLKMT2A
SCHEMBL6985505 0.82 MAPT (0.73) MAPTPIM1LMNAKMT2AALDH1A1
SCHEMBL73410 0.82 LMNA (0.68) MAPTLMNARECQLKMT2AALDH1A1
SCHEMBL26244629 0.81 MAOB (0.52) MAPTLMNAKMT2AALDH1A1HDAC4
SCHEMBL2104436 0.79 ERN1 (0.41) MAPTLMNAALDH1A1HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760773-B2 Small molecule drug conjugates of gemcitabine monophosphate MAVERIX ONCOLOGY, INC. (US) 2023-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760773-B2 Small molecule drug conjugates of gemcitabine monophosphate ZYX, SLC7A5, GMPS MAPT 4486/4885PIM1 2693/4885LMNA 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.